InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,508.57
(
-0.65%
)
US TECH 100
19,022.00
(
-0.82%
)
Dow Jones
40,271.21
(
-0.97%
)
Brent Oil
82.46
(
-1.93%
)
Bitcoin
66,249.72
(
3.57%
)
Post# of 252639
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120079
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: north40000 post# 95189

Tuesday, 05/04/2010 6:58:45 PM

Tuesday, May 04, 2010 6:58:45 PM

Post# of 252639
Sirtris’ IP estate included a number of analogs. If the safety problem with SRT501 is compound-specific, the sirtuin program could still bear fruit. On the other hand, if the problem with SRT501 is mechanistic, GSK wasted a lot of money. For what GSK paid to acquire Sirtris, they could have bought IDIX (instead of partnering with them).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up